Skip to content

Progress in Neuro-Psychopharmacology and Biological Psychiatry

ISSN 1878-4216, 0278-5846

154 papers in the library · 1,492 citations · publishing 1985-2026

Papers

Sort Most recent Most cited

Electroconvulsive therapy disrupts functional connectivity between hippocampus and posterior default mode network.

Progress in Neuro-Psychopharmacology and Biological Psychiatry February 1, 2024 K. Gbyl, Vytautas Labanaukas, C. C. Lundsgaard et al.

BACKGROUND The mechanisms underlying memory deficits after electroconvulsive therapy (ECT) remain unclear but altered functional interactions between hippocampus and neocortex may play a role. OBJECTIVES To test whether ECT reduces functional connectivity between hippocampus and posterior regions of the default mode network (DMN) and to examine whether altered hippocampal-neocortical functional...

MDMA-assisted psychotherapy for PTSD: Growing evidence for memory effects mediating treatment efficacy.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2024 Mesud Sarmanlu, Kim P. C. Kuypers, Patrick Vizeli et al. 17 citations

The application of MDMA in conjunction with psychotherapy has in recent years seen a resurgence of clinical, scientific, and public interest in the treatment of posttraumatic stress disorder (PTSD). Clinical trials have shown promising safety and efficacy, but the mechanisms underlying this treatment form remain largely unestablished. This article explores recent preclinical and clinical...

The mechanistic basis for the rapid antidepressant-like effects of ketamine: From neural circuits to molecular pathways.

Progress in Neuro-Psychopharmacology and Biological Psychiatry December 1, 2023 Li Ren

Conventional antidepressants that target monoaminergic receptors require several weeks to be efficacious. This lag represents a significant problem in the currently available treatments for serious depression. Ketamine, acting as an N-methyl-d-aspartate receptor antagonist, was shown to have rapid antidepressant-like effects, marking a significant advancement in the study of mood disorders....

The current state of ayahuasca research in animal models: A systematic review.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 13, 2023 Dimitri Daldegan-Bueno, Natalia Maria Simionato, Vanessa Manchim Favaro et al. 18 citations

The psychedelic brew ayahuasca is increasingly being investigated for its therapeutic potential. Animal models are essential to investigate the pharmacological effects of ayahuasca since they can control important factors influencing it, such as the set and setting. Review and summarise data available on ayahuasca research using animal models. We systematically searched five databases (PubMed,...

Investigating the "two-hit hypothesis": Effects of prenatal maternal immune activation and adolescent cannabis use on neurodevelopment in mice.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2023 Elisa Guma, Lani Cupo, Weiya Ma et al.

Prenatal exposure to maternal immune activation (MIA) and chronic adolescent cannabis use are both risk factors for neuropsychiatric disorders. However, exposure to a single risk factor may not result in major mental illness, indicating that multiple exposures may be required for illness onset. Here, we examine whether combined exposure to prenatal MIA and adolescent...

DOI: 10.1016/j.pnpbp.2022.110642 (opens in new tab) Full text (opens in new tab) Adolescent cannabis use Brain development Environmental risk factors Maternal immune activation +1

Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression.

Progress in Neuro-Psychopharmacology and Biological Psychiatry December 20, 2022 John Cook, Angelos Halaris

Esketamine is a novel treatment for treatment resistant depression (TRD) and was approved by the FDA in early 2019. It antagonizes the NMDA receptor providing rapid improvement in symptoms with a complex mechanism of action primarily mediated through glutamatergic activation. Significant barriers exist to widespread use of esketamine including durability of response, particularly in the...

Fast antidepressant action of ketamine in mouse models requires normal VGLUT1 levels from prefrontal cortex neurons.

Progress in Neuro-Psychopharmacology and Biological Psychiatry October 1, 2022 Francisco de Borja Belloch, M. Cortés-Erice, E. Herzog et al.

The NMDA antagonist ketamine demonstrated a fast antidepressant activity in treatment-resistant depression. Pre-clinical studies suggest that de novo synthesis of the brain-derived neurotrophic factor (BDNF) in the PFC might be involved in the rapid antidepressant action of ketamine. Applying a genetic model of impaired glutamate release, this study aims to further identify the molecular...

Molecular mechanisms underlying the N-methyl-d-aspartate receptor antagonists: Highlighting their potential for transdiagnostic therapeutics.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 1, 2022 Christina Driver, Timothy N. W. Jackson, Jim Lagopoulos et al.

The so-called "psychedelic renaissance" has stimulated expanded interest in several classes of drugs that appear to possess transdiagnostic effects in the treatment of mental health disorders, specifically. N-methyl-d-aspartate receptor (NMDAR) antagonists are one such class with diverse therapeutic potential. NMDARs mediate excitatory postsynaptic signalling in the central nervous system (CNS)...

Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): Impact on neurotropic, neurotrophic, and neuroplasticity signaling

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 28, 2022 Antonio Inserra, Antonella Campanale, David Cheishvili et al. 39 citations

AimPsychedelic compounds elicit relief from mental disorders. However, the underpinnings of therapeutic improvement remain poorly understood. Here, we investigated the effects of repeated lysergic acid diethylamide (LSD) on whole-genome DNA methylation and protein expression in the mouse prefrontal cortex (PFC).MethodsWhole genome bisulphite sequencing (WGBS) and proteomics profiling of the...

DOI: 10.1016/j.pnpbp.2022.110594 (opens in new tab) Neuroplasticity Prefrontal cortex Modulation music Cell biology +4

Niacin mitigates blood-brain barrier tight junctional proteins dysregulation and cerebral inflammation in ketamine rat model of psychosis: Role of GPR109A receptor.

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 8, 2022 Weam W Ibrahim, R. H. Sayed, Esraa A Kandil et al.

Dysregulated inflammatory responses and blood-brain barrier (BBB) dysfunction are recognized as central factors in the development of psychiatric disorders. The present study was designed to evaluate the effect of niacin on BBB integrity in ketamine-induced model of psychosis. Meanwhile, mepenzolate bromide (MPN), a GPR109A receptor blocker, was used to investigate the role of this receptor on...

Separate and combined effects of alcohol and cannabis on mood, subjective experience, cognition and psychomotor performance: A randomized trial.

Progress in Neuro-Psychopharmacology and Biological Psychiatry May 1, 2022 Christine M Wickens, Madison Wright, R. Mann et al.

Co-use of alcohol and cannabis is associated with increased frequency and intensity of use and related problems. This study examined acute effects of alcohol and cannabis on mood, subjective experience, cognition, and psychomotor performance. Twenty-eight healthy cannabis users aged 19-29 years with recent history of binge drinking completed this within-subjects, double-blind, double-dummy,...

Ketamine administration in early postnatal life as a tool for mimicking Autism Spectrum Disorders core symptoms.

Progress in Neuro-Psychopharmacology and Biological Psychiatry April 1, 2022 M. Bove, Stefania Schiavone, Paolo Tucci et al.

Autism Spectrum Disorders (ASD) core symptoms include deficits of social interaction, stereotyped behaviours, dysfunction in language and communication. Beyond them, several additional symptoms, such as cognitive impairment, anxiety-like states and hyperactivity are often occurring, mainly overlapping with other neuropsychiatric diseases. To untangle mechanisms underlying ASD etiology, and to...

Endocannabinoid system contributions to sex-specific adolescent neurodevelopment.

Progress in Neuro-Psychopharmacology and Biological Psychiatry March 8, 2022 Jonathan J. Simone, Matthew R Green, Cheryl M McCormick

With an increasing number of countries and states adopting legislation permitting the use of cannabis for medical purposes, there is a growing interest among health and research professionals into the system through which cannabinoids principally act, the endocannabinoid system (ECS). Much of the seminal research into the ECS dates back only 30 years and, although there has been tremendous...

DOI: 10.1016/j.pnpbp.2021.110438 (opens in new tab) Full text (opens in new tab) Adolescence Behaviour Cb1 receptor Endocannabinoid +2

Prophylactic efficacy of ketamine, but not the low-trapping NMDA receptor antagonist AZD6765, against stress-induced maladaptive behavior and 4E-BP1-related synaptic protein synthesis impairment.

Progress in Neuro-Psychopharmacology and Biological Psychiatry 2022 A. Camargo, A. C. N. Torrá, A. P. Dalmagro et al.

Ketamine enhances the resilience against stress-induced depressive-like behavior, but its prophylactic efficacy in anxiety-related behaviors remains to be elucidated. Moreover, there is a need for developing novel preventive strategies against depressive- and anxiety-like behavior. AZD6765, a low-trapping NMDA receptor antagonist, shares with ketamine common molecular targets and produces...

THC and CBD produce divergent effects on perception and panic behaviours via distinct cortical molecular pathways.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2021 Hanna J Szkudlarek, Mar Rodríguez-ruiz, Roger Hudson et al.

Clinical and pre-clinical evidence demonstrates divergent psychotropic effects of THC vs. CBD. While THC can induce perceptual distortions and anxiogenic effects, CBD displays antipsychotic and anxiolytic properties. A key brain region responsible for regulation of cognition and affect, the medial prefrontal cortex (PFC), is strongly modulated by cannabinoids, suggesting that these dissociable...

DOI: 10.1016/j.pnpbp.2020.110029 (opens in new tab) Full text (opens in new tab) Cannabinoids Latent inhibition Panic Prefrontal cortex

The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 2, 2021 Agnieszka Pałucha-Poniewiera, K. Podkowa, Anna Rafało-Ulińska

Ketamine produces a rapid antidepressant effect, but its use can be associated with serious side effects. Hence, other therapeutic options that will allow us to obtain a quick and safe antidepressant effect by modulating glutamatergic transmission are needed. Antagonists of mGlu2/3 receptors, which share some mechanisms of action with ketamine, may be good candidates to obtain this effect....

Differential effects of cannabis exposure during early versus later adolescence on the expression of psychosis in homeless and precariously housed adults.

Progress in Neuro-Psychopharmacology and Biological Psychiatry September 2, 2020 K. Gicas, Alex Y T Cheng, William J. Panenka et al.

Longitudinal studies of cannabis exposure during early adolescence in the general population frequently report an increased risk of subsequently developing psychotic symptoms or a psychotic illness. However, there is a dearth of knowledge about the effects of early cannabis exposure on psychosis in homeless and precariously housed adults, who represent a population afflicted with high rates of...

Acute effects of partial CB1 receptor agonists on cognition - A meta-analysis of human studies.

Progress in Neuro-Psychopharmacology and Biological Psychiatry August 10, 2020 Simon Zhornitsky, Julie Pelletier, Roxane Assaf et al.

BACKGROUND Impairment in cognition is frequently associated with acute cannabis consumption. However, some questions remain unanswered as to which deficits are most prominent and which demographic groups are most vulnerable. METHODS A literature search yielded 40 experimental studies of acute administration of partial CB1 receptor agonists (i.e. cannabis, THC, and nabilone) that assessed...

Ketamine induces rapid and sustained antidepressant-like effects in chronic pain induced depression: Role of MAPK signaling pathway.

Progress in Neuro-Psychopharmacology and Biological Psychiatry February 25, 2020 Muris Humo, Beyza Ayazgök, Léa J. Becker et al.

Chronic pain produces psychologic distress, which often leads to mood disorders such as depression. Co-existing chronic pain and depression pose a serious socio-economic burden and result in disability affecting millions individuals, which urges the development of treatment strategies targeting this comorbidity. Ketamine, a noncompetitive antagonist of the N-methyl-d-aspartate (NMDA) receptor,...

Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis.

Progress in Neuro-Psychopharmacology and Biological Psychiatry 2020 Anees Bahji, Ashleigh Forsyth, D. Groll et al. 85 citations

BACKGROUND Posttraumatic stress disorder (PTSD) is a common psychiatric condition that can develop following a traumatic experience. PTSD is associated with significant disability, a large economic burden, and despite the range of therapies to treat PTSD, response to antidepressants is limited. A growing body of clinical research suggests the efficacy of 3,4-methylenedioxymethamphetamine...

Ketamine administration induces early and persistent neurochemical imbalance and altered NADPH oxidase in mice.

Progress in Neuro-Psychopharmacology and Biological Psychiatry 2020 Stefania Schiavone, M. Morgese, M. Bove et al.

Administration in adulthood of subanaesthetic doses of ketamine, an NMDA receptor (NMDA-R) antagonist, is commonly used to induce psychotic-like alterations in rodents. The NADPH oxidase (NOX) derived-oxidative stress has been shown to be implicated in ketamine-induced neurochemical dysfunctions and in the loss of parvalbumin (PV)-positive interneurons associated to the administration of this...

Schizophrenia, cannabis use and Catechol‐O‐Methyltransferase (COMT): Modeling the interplay on cognition

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 1, 2019 Marta Bosia, M. Buonocore, M. Bechi et al.

&NA; Cognitive impairments are considered core features of schizophrenia and are recognized as the most important predictors of functional outcome and quality of life. A better study of the mechanisms underlying the cognition is of extreme relevance. Literature has shown that several genetic and environmental factors affect cognitive performance. In particular, the interaction between...

The interaction between the ZNF804A gene and cannabis use on the risk of psychosis in a non‐clinical sample

Progress in Neuro-Psychopharmacology and Biological Psychiatry March 1, 2019 Joaquim Soler, Bárbara Arias, Jorge Moya et al.

ABSTRACT The ZNF804A gene and cannabis use are risk factors for psychosis and both have also been associated with schizotypal traits. This study aimed to investigate: i) the association of lifetime cannabis use (and its dose effect) with schizotypal personality traits, and ii) whether the genetic variability at ZNF804A gene modulates that association. Our sample consisted of 385 Spanish...

Ketamine promotes rapid and transient activation of AMPA receptor-mediated synaptic transmission in the dorsal raphe nucleus.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2019 Nerea Llamosas, Laura Perez-Caballero, Esther Berrocoso et al.

Accumulating evidence indicates that the antidepressant effects of ketamine are, in part, mediated by an increase in the AMPA receptor-mediated neurotransmission in depression related areas, such as the prefrontal cortex (PFC). Therefore, activity in PFC-projecting areas related to major depression, such as the dorsal raphe nucleus (DR), may also be modulated by ketamine. We used whole-cell...

Applying ketamine to alleviate the PTSD-like effects by regulating the HCN1-related BDNF.

Progress in Neuro-Psychopharmacology and Biological Psychiatry August 30, 2018 Lanwei Hou, Yirui Qi, Hongwei Sun et al.

Post-traumatic stress disorder (PTSD) is commonly associated with concurrent anxiety and depression symptoms, and reduce the expression of the Brain-Derived Neurotrophic Factor (BDNF) which promotes the proliferation and survival of neurons. The hyperpolarization-activated cyclic nucleotide-gated channel 1(HCN1) could be inhibited by the ketamine, a drug to alleviate depression and anxiety, and...